|
1
|
Hay ED: An overview of
epithelia-mesenchymal transformation. Acta Anat. 154:8–20. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalluri R and Weinberg RA: The basic of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transition in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Acloque H, Adams MA, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
the importance of changing cell state in development and disease. J
Clin Invest. 199:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foroni C, Broggini M, Generali D and Damia
G: Epithelial-mesenchymal transition and breast cancer: role,
molecular emchanisms and clinical impact. Cancer Treat Rev.
38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moreno-Bueno G, Portillo F and Cano A:
Transcriptional regulation of cell polarity in EMT and cancer.
Oncogene. 27:6958–6969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klymkikowsky MW and Savagner P:
Epithelial-mesenchymal transition: a cancer researcher’s conceptual
friend and foe. Am J Pathol. 174:1588–1593. 2009.PubMed/NCBI
|
|
9
|
Ahmed N, Maines-Bandiera S, Quinn MA,
Unger WG, Dedhar S and Auersperg N: Molecular patheways regulating
EGF-induced epithelia-mesenchymal transition in human ovarian
surface epithelium. Am J Physiol Cell Physiol. 290:C1532–C1542.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhowmick NA, Chytil A, Plieth D, Gorska
AE, Dumont N, Shappell S, Washingtom MK, et al: TGF-β signaling in
fibroblasts modulation the oncogenic potential of adjacent
epithelia. Science. 6:848–851. 2004.
|
|
11
|
Suo Z, Risberg B, Karlsson MG, Villman K,
Skovlund E and Nesland JM: The expression of EGFR family ligands in
breast carcinoma. Int J Surg Pathol. 10:91–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramapul RS, Pinder SE, Wencyk PM,
Nicholson RI, Blamey RW, Robertson JF and Ellis IO: Epidermal
growth factor receptor status operable invasive cancer: is it of
any prognostic value? Clin Cancer Res. 10:25782004.PubMed/NCBI
|
|
13
|
Sasaki T, Hiroki K and Yamashita Y: The
role of epidermal growth factor receptor in cancer metastasis and
microenviromental. Biomed Res Int. 2013:5463182013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nieto MA: The snail superfamily of
zinc-finger transcription factors. Nat Rev Mol Cell Biol.
3:155–166. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hajra KM, Chen SY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|
|
16
|
Rosivatz E, Becker I, Specht K, Fricke E,
Luber B, Busch R, Höfler H, et al: Differential expression of the
epithelial-mesenchymal transition regulators Snail, SIP1, and twist
in gastric cancer. Am J Pathol. 161:1881–1891. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandewalle C, Van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, et al: N-cadherin expression and
epithelial-mesenchymal transition in pancreatic carcinoma. Clin
Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nijkamp MM, Span PN, Hoogsteen LJ, Van der
Kogel AJ, Kaanders JH and Bussink J: Expression of E-cadherin and
vimentin correlates with metastasis formation in head and neck
squamous cell carcinoma patients. Radiother Oncol. 99:344–348.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Benz PM, Blume C, Seifert S, Wilhelm S,
Waschke J, Schuh K, Gertler F, et al: Differential VASP
phosphorylation controls remodeling of the actin cytoskeleton. J
Cell Sci. 122:3954–3965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krause M, Dent EW, Bear JE, Loureiro JJ
and Gertler FB: Ena/VASP proteins: regulators of the actin
cytoskeleton and cell migration. Annu Rev Cell Dev Biol.
19:541–564. 2003.
|
|
22
|
Harbeck B, Hüttelmaier S, Schluter K,
Jockusch BM and Illenberger S: Phosphorylation of the
vasodilator-stimulated phosphoprotein regulates its interaction
with actin. J Biol Chem. 275:30817–30825. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He M, Cheng Y, Li W, Liu Q, Liu J, Huang J
and Fu X: Vascular endothelial growth factor C promotes cervical
cancer metastasis via up-regulation and activation of
RhoA/ROCK-2/moesin cascade. BMC Cancer. 10:1702010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
25
|
Colditz GA, Sellers TA and Trapido E:
Epidemiology - identifying cause and preventability of cancer? Nat
Rev Cancer. 6:75–83. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee SH, Kim GT, Kim JI, Lim EG, Kim IS and
Kim YM: The extract from Lysimachia foenum-graecum induce
apoptosis in MCF-7 breast cancer cells. KSSB J. 28:303–309.
2013.
|
|
27
|
Pan SY, Zhou SF, Gao SH, Yu ZL, Zhang SF,
Tang MK, Sun JN, et al: New perspectives on how to discover drugs
from herbal medicines: CAM’s outstanding contribution to modern
therapeutics. Evid Based Complement Alternat Med.
2013:62737582013.PubMed/NCBI
|
|
28
|
Shizhen Li: Ben Cao Gang Mu [Compendium of
Materia Medica]. China: 1593
|
|
29
|
Zhongjing Zhang: Shang han Lun [Treatise
on cold damage disorders]. China: pp. 220
|
|
30
|
Jones JL, Royall JE and Walker RA:
E-cadherin relates to EGFR expression and lymph node metastasis in
primary breast carcinoma. Br J Cancer. 74:1237–1241. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holz C, Niehr F, Boyko M, Hristozova T,
Distel L, Budach V and Tinhofer I:
Epithelial-mesenchymal-transition induced by EGFR activation
interferes with cell migration and response to irradiation and
cetuximab in head and neck cancer cells. Radiother Oncol.
101:158–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng JC, Auersperg N and Leung PC:
EGF-induced EMT and invasiveness in serous borderline ovarian tumor
cells: a possible step in the transition to low-grade serous
carcinoma cells? PLoS One. 7:e340712012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vergara D, Valente CM, Tinelli A,
Siciliano C, Lorusso V, Acierno R, Giovinazzo G, et al: Resveratrol
inhibits the epidermal growth factor-induced epithelial mesenchymal
trasition in MCF-7 cells. Cancer Lett. 310:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin Y, Iwata KK, Belldegrum A, Figlin R,
Pantuck A, Zhang ZF, Lieberman R, et al: Effect of an epidermal
growth factor receptor tyrosine kinase inhibitor in actin
remodeling in an in vitro bladder cancer carcinogenesis model. Mol
Cancer Ther. 5:1754–1765. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wallerand H, Cai Y, Wainberg ZA, Garraway
I, Lascombe I, Nicolle G, Thiery JP, et al: Phospho-Akt pathway
activation and inhibition depends on N-cadherin or phosphor-EGFR
expression in invasive human bladder cancer cell lines. Urol Oncol.
28:180–188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weigelt B, Peterse JL and van’t Veer LJ:
Breast cancer metastasis: markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pinder SE, Ellis IO, Galea M, O’Rouke S,
Blamey RW and Elston CW: Pathological prognostic factors in breast
cancer. III Vascular invasion: relationship with recurrence and
survival in a large study with long-term follow-up. Histopatology.
24:41–47. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Boer M, van Dijck JA, Bult P, Borm GF
and Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node
metastases, isolated tumor cells, and micrometastases. J Natl
Cancer Inst. 102:410–425. 2010.PubMed/NCBI
|
